The Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 pipeline drugs market research report outlays comprehensive information on the Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Immunology, and Gastrointestinal which include the indications Oncology, Lung Cancer, Glucose Transporter Type 1 Deficiency Syndrome (GLUT1 Deficiency Syndrome/De Vivo Disease), Autoimmune Disorders, Inflammation, Ulcerative Colitis, and Crohn’s Disease (Regional Enteritis). It also reviews key players involved in Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 pipeline targets constitutes close to ten molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 2 molecule.
Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 overview
Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 (SLC2A1), also known as GLUT1, is a membrane protein that functions as a glucose transporter, facilitating the transport of glucose across cell membranes. GLUT1 is widely expressed in various tissues and cell types, including red blood cells, endothelial cells of the blood-brain barrier, and cells with high energy demands, such as neurons. The transport of glucose by GLUT1 is facilitated by its ability to recognize and bind to glucose molecules, allowing their translocation across the cell membrane. In the context of the blood-brain barrier, GLUT1 plays a crucial role in transporting glucose from the bloodstream into the brain, ensuring a continuous energy supply for neuronal function. Mutations or dysregulation of SLC2A1/GLUT1 have been associated with GLUT1 deficiency syndrome, a rare genetic disorder characterized by impaired glucose transport to the brain, leading to neurological symptoms.
For a complete picture of Solute Carrier Family 2 Facilitated Glucose Transporter Member 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
